Summit Therapeutics Current Cash

Summit Therapeutics (SMMT) currently reports a current cash of $420M as of June 2026. That compares with $300M in the prior-year period — up 40.8% year over year. Use the charts on this page to explore Summit Therapeutics's current cash history and peer comparisons.

Summit Therapeutics's current cash increased from $300M to $420M — a 40.8% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Summit Therapeutics reported $420M in current cash as of June 2026. That compares with $300M in the prior-year period — up 40.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $420M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Summit Therapeutics, and consider following SMMT for alerts when major investors trade the stock.